One of the biggest sources of stress on the heart from smoking analogs is the carbon monoxide it adds to your blood.
CO binds to hemoglobin and reduces the blood oxygen carrying capacity, and your heart has to work harder and harder.
Unfortunately, because CO binds to hemoglobin irreversibly, you have to wait 2-5 years for your body to make all new blood.
That's not really a blood pressure issue, but it's another heart stress issue that is gradually improving for us all as we quit/reduce analogs.
It's also worth considering that
blood pressure is one of those indicators that is really sensitive to a lot of things: it can be raised by dietary salt, stress, sleep deprivation, weight gain (even minor gain!), other medications you are taking (including common ones like the birth control pill), reduced athletic activity, caffeine intake, hormonal changes, other underlying conditions......and surely more that I don't know.
Nicotine =/= huge cardiovascular risks. It is nicotine in combination with SMOKE (and especially the resulting carbon monoxide) that causes all the harm. Here are a few resources on this topic.
And from Harm Reduction Journal :
HRJ | Full text | Tobacco harm reduction: an alternative cessation strategy for inveterate smokers
"Over the past 15 years, eight epidemiologic studies have examined the risk of cardiovascular diseases among ST users. Six of the studies found that ST users had no increased risk for heart attacks or strokes [47,90,97-100] . The other two reported modestly positive associations, with ST users having RRs of 1.2 and 1.4 [92,101] , which are lower than those of smokers. In 2003, Asplund completed a comprehensive review of the cardiovascular effects of ST use [102] . He concluded that, in distinct contrast to smokers, ST users do not exhibit any significant differences from nonusers of tobacco with regard to the following measures of cardiovascular health: heart rate, blood pressure, cardiac output and maximal working capacity, levels of hemoglobin and hematocrit, leukocytes, antioxidant vitamins, fibrinogen, components of the fibrinolytic system, C-reactive protein and thromboxane A2 production. In addition, ST users did not show important smoking-associated vascular changes, including increased thickness of blood vessels and atherosclerotic plaque development. In summary, most of the medical and epidemiologic evidence documents that ST users do not have elevated risks for cardiovascular diseases."